Market Access
Gain high value access and increase the profitability of your brands
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
WHO WE HELP
-
Pharmaceutical Manufacturers
-
Emerging Biopharma
-
MedTech
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MorePharmaceutical Manufacturers
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsMedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover More
Medical Specialty and Patient Advocacy
Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Explore NowU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSBlog
Exclusion List Exposure: The Case for Proactive, Data-driven Monitoring and Prevention – Part 3 of 3 in a Series
Nov 06, 2023
From delivering dangerous treatments to billing for services not rendered, there are a host of reasons why a healthcare provider or entity could end up on federal and/or state Exclusion Lists. As we explained in our first and second posts, despite the existence of these lists, “bad actors” continue to deliver care and submit claims. In fact, an IQVIA analysis revealed a jaw-dropping $893 million in estimated drug expenditures in 2021 and 2022 from members on “bad actor” lists.
For pharmaceutical companies, this finding points to significant compliance risk. It suggests opportunities to tighten up commercial practices. And it opens the door to a much larger financial exposure: rebates paid to and through individuals and entities on Exclusion Lists.
Within many companies, there hasn't been a high level of awareness about Exclusion List exposure. As market conditions become more challenging, it’s critical that leaders from the C-suite to Market Access and Compliance teams become more aware of these risks.
Can you quantify your organization’s current exposure to Exclusion Lists? What steps are you taking to reduce that exposure? What are the benefits of adopting a more proactive, preventive approach over the long term?
Understand your current state
If you don’t already have a clear understanding of your current exposure, consider performing a data-driven audit of your individual company. IQVIA’s Gross-to-Net team has experience with such audits. The process requires your company to provide IQVIA with rebate claims for the drugs to be analyzed. Our team then flags rebate claims where the fill date falls within an exclusion period and creates a summary of results by list category.
At the same time, consider incorporating an additional review of claims from deactivated NPIs, as well as those from Medicare opt-out HCPs, as measures to improve program integrity and reduce potential exposure to fraudulent activity.
Conduct ongoing monitoring
A one-time audit is an excellent starting point, but not sufficient to reduce risk exposure over time. To that end, organizations need to invest in proactive monitoring of Exclusion Lists. This requires connecting data to help eliminate gaps where bad actors can create compliance risks and unintended consequences in contracting and rebating processes.
Realize the benefits of a proactive approach
IQVIA experience points to three key advantages of a more proactive approach:
- Stay abreast of exposure risk. Having a data-driven audit strategy creates a foundation for tracking rebates being paid and developing key performance indicators as part of your compliance program. Only through regular monitoring can you promptly identify (and address) Exclusion List exposure. How do you know your exposure unless there is regular monitoring?
- Stop paying rebates based on excluded claims. Once you have a handle on exposure risk, you can create policies around these complex risk areas and include terms in contracts with payers. You can then develop business rules based on those policies and terms — helping prevent payment of rebates based on excluded claims.
- Strengthen your gross-to-net and market access brand strategies. Ongoing monitoring, internal policies, contract terms, and business rules should be integrated into the design of patient assistance programs and incorporated into your healthcare provider targeting strategy.
Connect the dots, reduce the risk
With a proactive, data-driven approach, your organization can avoid the risk of doing business with excluded healthcare providers and entities. IQVIA has a unique combination of data sources and expertise to help you connect all the dots — and support your compliance, program integrity, and contracting effectiveness goals.
IQVIA’S Market Access Center of Excellence
In a time when better access has never mattered more, IQVIA has built the largest and most experienced market access team in the industry. That team of experts drives IQVIA’s Market Access Center of Excellence, powered by intelligent connections between data, analytics, technology, and strategy to help clients navigate today’s challenging access environment.